Clinical trial
A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
NCT04419623 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
- Lead sponsor
- Telios Pharma, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 9, 2020
- Completion date
- December 15, 2020
- Enrollment
- 7 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.